{"id":"W2991496398","doi":"10.1007/s13555-019-00340-3","title":"Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure","year":2019,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":67,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Cilag; Sanofi Genzyme; Genentech; Medac; Mitsubishi Tanabe Pharma Corporation; Sanofi; Kyowa Hakko Kirin; LEO Fondet; Astellas Pharma; Regeneron Pharmaceuticals; Mylan; Eli Lilly and Company; Purdue Pharma; Sun Pharma; Dermira; Purdue University; Coherus Biosciences; UCB Pharma; Valeant Pharmaceuticals International; Baxalta; Celgene; Pfizer; Biogen; GlaxoSmithKline; Amgen; Meiji Seika Pharma; Galderma; LEO Pharma; Ortho Dermatologics; Allergan; AstraZeneca; Samsung; Bristol-Myers Squibb","keywords":"Ixekizumab; Psoriasis; Medicine; Dermatology; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01048356,0.0004368138,0.001169409,0.0008706847,0.0002289887,0.001105249,0.0003335585,0.0005784169,0.001566147],"category_scores_gemma":[0.006324719,0.0002707978,0.003044456,0.001345111,0.0002733711,0.0007344997,0.0005638795,0.0007476738,0.0002247909],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003991058,"about_ca_system_score_gemma":0.0005050669,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000565398,"about_ca_topic_score_gemma":0.0008174902,"domain_scores_codex":[0.9953808,0.001677662,0.0008765479,0.0007421467,0.001158554,0.0001642953],"domain_scores_gemma":[0.9890741,0.003268863,0.005411371,0.0008492359,0.001018373,0.0003782124],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01691503,0.0005024383,0.8711049,0.001671684,0.01445626,0.0001924528,0.0002231883,0.001251535,0.003321165,0.00007368798,0.0009804808,0.08930711],"study_design_scores_gemma":[0.001494614,0.01002042,0.973708,0.0003327149,0.007418324,0.001167626,0.0001038477,0.0005647997,0.001453174,0.0001286977,0.003575255,0.0000325454],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9374637,0.05464844,0.001531938,0.0002525719,0.00003798899,0.0002484338,0.003254928,0.00004815457,0.00251376],"genre_scores_gemma":[0.991454,0.005445201,0.0005345481,0.0001479457,0.00009378985,0.0001041963,0.001997538,0.000007748163,0.000214958],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01048356,"threshold_uncertainty_score":0.05544305,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009983924242019151,"score_gpt":0.2114780800689378,"score_spread":0.2014941558269186,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}